A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis (CRS) is a chronic disease of the upper airways that is both common, as it affects more than 10 million Americans1, and economically onerous, as it is associated an annual loss of 60 paid work days missed per patient from both absenteeism and presenteeism2. CRS is associated with a significant decline in quality of life (QOL)3. The majority of CRS patients do not improve with current medical options and need to undergo repetitive surgeries. Not surprisingly, CRS is associated with a high financial burden on society with an estimated 60 billion dollars per year 4.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: CME Reviews Source Type: research